1051 related articles for article (PubMed ID: 21123111)
1. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials.
Bangalore S; Kumar S; Kjeldsen SE; Makani H; Grossman E; Wetterslev J; Gupta AK; Sever PS; Gluud C; Messerli FH
Lancet Oncol; 2011 Jan; 12(1):65-82. PubMed ID: 21123111
[TBL] [Abstract][Full Text] [Related]
2. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: a meta-analysis and meta-regression of randomised controlled trials.
Shahin Y; Khan JA; Chetter I
Atherosclerosis; 2012 Mar; 221(1):18-33. PubMed ID: 22209214
[TBL] [Abstract][Full Text] [Related]
4. Beta-blockers for hypertension.
Wiysonge CS; Bradley H; Mayosi BM; Maroney R; Mbewu A; Opie LH; Volmink J
Cochrane Database Syst Rev; 2007 Jan; (1):CD002003. PubMed ID: 17253471
[TBL] [Abstract][Full Text] [Related]
5. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
[TBL] [Abstract][Full Text] [Related]
6. Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis.
Copland E; Canoy D; Nazarzadeh M; Bidel Z; Ramakrishnan R; Woodward M; Chalmers J; Teo KK; Pepine CJ; Davis BR; Kjeldsen S; Sundström J; Rahimi K;
Lancet Oncol; 2021 Apr; 22(4):558-570. PubMed ID: 33794209
[TBL] [Abstract][Full Text] [Related]
7. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Anti-Hypertensive Therapy and Stroke Prevention: A Meta-Analysis.
Mukete BN; Cassidy M; Ferdinand KC; Le Jemtel TH
Am J Cardiovasc Drugs; 2015 Aug; 15(4):243-57. PubMed ID: 26055616
[TBL] [Abstract][Full Text] [Related]
9. Do all antihypertensive drugs improve carotid intima-media thickness? A network meta-analysis of randomized controlled trials.
Tropeano AI; Saleh N; Hawajri N; Macquin-Mavier I; Maison P
Fundam Clin Pharmacol; 2011 Jun; 25(3):395-404. PubMed ID: 20584209
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials.
Shahin Y; Khan JA; Samuel N; Chetter I
Atherosclerosis; 2011 May; 216(1):7-16. PubMed ID: 21411098
[TBL] [Abstract][Full Text] [Related]
11. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.
Psaty BM; Lumley T; Furberg CD; Schellenbaum G; Pahor M; Alderman MH; Weiss NS
JAMA; 2003 May; 289(19):2534-44. PubMed ID: 12759325
[TBL] [Abstract][Full Text] [Related]
12. Calcium channel blockers versus other classes of drugs for hypertension.
Zhu J; Chen N; Zhou M; Guo J; Zhu C; Zhou J; Ma M; He L
Cochrane Database Syst Rev; 2022 Jan; 1(1):CD003654. PubMed ID: 35000192
[TBL] [Abstract][Full Text] [Related]
13. Calcium channel blockers versus other classes of drugs for hypertension.
Zhu J; Chen N; Zhou M; Guo J; Zhu C; Zhou J; Ma M; He L
Cochrane Database Syst Rev; 2021 Oct; 10(10):CD003654. PubMed ID: 34657281
[TBL] [Abstract][Full Text] [Related]
14. A meta-analysis of the effect of angiotensin receptor blockers and calcium channel blockers on blood pressure, glycemia and the HOMA-IR index in non-diabetic patients.
Yang Y; Wei RB; Xing Y; Tang L; Zheng XY; Wang ZC; Gao YW; Li MX; Chen XM
Metabolism; 2013 Dec; 62(12):1858-66. PubMed ID: 24050270
[TBL] [Abstract][Full Text] [Related]
15. Comparative risk of new-onset diabetes mellitus for antihypertensive drugs in elderly: A Bayesian network meta-analysis.
Zhang J; Tong A; Dai Y; Niu J; Yu F; Xu F
J Clin Hypertens (Greenwich); 2019 Aug; 21(8):1082-1090. PubMed ID: 31241860
[TBL] [Abstract][Full Text] [Related]
16. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.
ARB Trialists Collaboration
J Hypertens; 2011 Apr; 29(4):623-35. PubMed ID: 21358417
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
Petrella R; Michailidis P
Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
[TBL] [Abstract][Full Text] [Related]
18. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
Talbert RL
J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
[TBL] [Abstract][Full Text] [Related]
19. Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis.
Zhao HJ; Li Y; Liu SM; Sun XG; Li M; Hao Y; Cui LQ; Wang AH
Ren Fail; 2016 Jul; 38(6):849-56. PubMed ID: 27055479
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
Volpe M; Tocci G; Sciarretta S; Verdecchia P; Trimarco B; Mancia G
J Hypertens; 2009 May; 27(5):941-6. PubMed ID: 19381108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
